Mark Beresford

3.3k total citations · 1 hit paper
50 papers, 1.7k citations indexed

About

Mark Beresford is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Mark Beresford has authored 50 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 18 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Cancer Research. Recurrent topics in Mark Beresford's work include Breast Cancer Treatment Studies (15 papers), MRI in cancer diagnosis (9 papers) and Radiomics and Machine Learning in Medical Imaging (6 papers). Mark Beresford is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), MRI in cancer diagnosis (9 papers) and Radiomics and Machine Learning in Medical Imaging (6 papers). Mark Beresford collaborates with scholars based in United Kingdom, United States and Australia. Mark Beresford's co-authors include Andreas Makris, George D. Wilson, Anwar R. Padhani, Richard Benson, Thankamma Ajithkumar, David Gillatt, N. Jane Taylor, David J. Collins, James Stirling and Mei-Lin W. Ah-See and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Radiology.

In The Last Decade

Mark Beresford

47 papers receiving 1.7k citations

Hit Papers

Trastuzumab emtansine plu... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
    2020 280 citations Leisha A. Emens, Francisco J. Esteva et al. The Lancet Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark Beresford 727 575 445 376 325 50 1.7k
Noh-Hyun Park 441 0.6× 432 0.8× 327 0.7× 238 0.6× 297 0.9× 77 2.1k
Aurélie Bertaut 838 1.2× 167 0.3× 590 1.3× 291 0.8× 330 1.0× 105 1.8k
Christian Wülfing 508 0.7× 207 0.4× 786 1.8× 356 0.9× 634 2.0× 113 1.9k
Nicola Battelli 1.0k 1.4× 180 0.3× 814 1.8× 553 1.5× 291 0.9× 91 1.9k
Gillian C. Barnett 535 0.7× 994 1.7× 728 1.6× 684 1.8× 227 0.7× 41 2.1k
Fritz Jaenicke 353 0.5× 179 0.3× 184 0.4× 308 0.8× 467 1.4× 54 1.4k
Javier Puente 786 1.1× 85 0.1× 639 1.4× 426 1.1× 320 1.0× 164 1.5k
Hiroshi Yagata 487 0.7× 338 0.6× 214 0.5× 627 1.7× 133 0.4× 70 1.2k
Vivek Narayan 837 1.2× 186 0.3× 830 1.9× 327 0.9× 216 0.7× 99 1.8k
Stuart McIntosh 503 0.7× 173 0.3× 456 1.0× 466 1.2× 480 1.5× 91 1.5k

Countries citing papers authored by Mark Beresford

Since Specialization
Citations

This map shows the geographic impact of Mark Beresford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Beresford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Beresford more than expected).

Fields of papers citing papers by Mark Beresford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Beresford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Beresford. The network helps show where Mark Beresford may publish in the future.

Co-authorship network of co-authors of Mark Beresford

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Beresford. A scholar is included among the top collaborators of Mark Beresford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Beresford. Mark Beresford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oikonomidou, Olga, Mark Beresford, Rohan Parikh, et al.. (2025). Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2− advanced breast cancer in Europe. Breast Cancer Research and Treatment. 213(3). 299–312.
2.
Beresford, Mark, et al.. (2023). The effects of exercise training for eight weeks on immune cell characteristics among breast cancer survivors. Frontiers in Sports and Active Living. 5. 1163182–1163182. 4 indexed citations
3.
Beresford, Mark, et al.. (2023). Immune cell status, cardiorespiratory fitness and body composition among breast cancer survivors and healthy women: a cross sectional study. Frontiers in Physiology. 14. 1107070–1107070. 6 indexed citations
4.
5.
Beresford, Mark, John P. Campbell, Robert H. Jones, et al.. (2021). A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling. Frontiers in Immunology. 11. 616188–616188. 5 indexed citations
6.
Emens, Leisha A., Francisco J. Esteva, Mark Beresford, et al.. (2020). Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. The Lancet Oncology. 21(10). 1283–1295. 280 indexed citations breakdown →
7.
Wiltshire, Gareth, Mike Osborn, Sarah Wexler, et al.. (2020). The experiences of cancer patients within the material hospital environment: Three ways that materiality is affective. Social Science & Medicine. 264. 113402–113402. 6 indexed citations
8.
9.
Cain, Henry, et al.. (2017). Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice. Clinical Oncology. 29(10). 642–652. 87 indexed citations
10.
Palmieri, Carlo, Iain R. Macpherson, Felipe Ades, et al.. (2015). Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget. 7(11). 13209–13220. 4 indexed citations
11.
Beresford, Mark, et al.. (2013). Searching for Prostate Cancer Stem Cells: Markers and Methods. Stem Cell Reviews and Reports. 9(5). 721–730. 52 indexed citations
12.
Li, Sonia P., Anwar R. Padhani, N. Jane Taylor, et al.. (2011). Vascular characterisation of triple negative breast carcinomas using dynamic MRI. European Radiology. 21(7). 1364–1373. 69 indexed citations
13.
Li, Sonia P., Andreas Makris, Mark Beresford, et al.. (2011). Use of Dynamic Contrast-enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadjuvant Chemotherapy. Radiology. 260(1). 68–78. 86 indexed citations
14.
Li, Sonia P., N. Jane Taylor, Andreas Makris, et al.. (2010). Primary Human Breast Adenocarcinoma: Imaging and Histologic Correlates of Intrinsic Susceptibility-weighted MR Imaging before and during Chemotherapy. Radiology. 257(3). 643–652. 45 indexed citations
15.
Beresford, Mark, David J. Stott, & Andreas Makris. (2007). Assessment of clinical response after two cycles of primary chemotherapy in breast cancer. Breast Cancer Research and Treatment. 109(2). 337–342. 14 indexed citations
16.
Beresford, Mark, Iain Lyburn, Bal Sanghera, Andreas Makris, & Wai‐Lup Wong. (2007). Serial Integrated18F-Fluorodeoxythymidine PET/CT Monitoring Neoadjuvant Chemotherapeutic Response in Invasive Ductal Carcinoma. The Breast Journal. 13(4). 424–425. 8 indexed citations
17.
Chin, Yaw Sinn, Mark Beresford, D. Ravichandran, & Andreas Makris. (2007). Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. The Breast. 16(4). 436–439. 24 indexed citations
18.
Beresford, Mark, D. Ravichandran, & Andreas Makris. (2006). Neoadjuvant endocrine therapy in breast cancer. Cancer Treatment Reviews. 33(1). 48–57. 8 indexed citations
19.
Beresford, Mark, George D. Wilson, & Andreas Makris. (2006). Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Research. 8(6). 216–216. 155 indexed citations
20.
Beresford, Mark, Anwar R. Padhani, N. Jane Taylor, et al.. (2006). Inter‐ and intraobserver variability in the evaluation of dynamic breast cancer MRI. Journal of Magnetic Resonance Imaging. 24(6). 1316–1325. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Noh-Hyun Park Breakdown of academic impact, for papers by Aurélie Bertaut Breakdown of academic impact, for papers by Christian Wülfing Breakdown of academic impact, for papers by Nicola Battelli Breakdown of academic impact, for papers by Gillian C. Barnett Breakdown of academic impact, for papers by Fritz Jaenicke Breakdown of academic impact, for papers by Javier Puente Breakdown of academic impact, for papers by Hiroshi Yagata Breakdown of academic impact, for papers by Vivek Narayan Breakdown of academic impact, for papers by Stuart McIntosh
Rankless by CCL
2026